Interim Considerations Preparing for the Potential Management of Anaphylaxis at COVID-19 Vaccination Sites

Centers for Disease Control and Prevention. (2020). Interim Considerations: Preparing for the Potential Management of Anaphylaxis at COVID-19 Vaccination Sites. (Added 12/30/2020.) U.S. Department of Health and Human Services.
This page offers information to help vaccination sites prepare for the initial assessment and management of anaphylaxis following COVID-19 vaccination. It identifies signs and symptoms for early recognition, lists medications and supplies recommended to be available at the site, instructs what steps to follow if anaphylaxis is suspected, and provides information on the post-vaccination observation period, patient counseling, and reporting of adverse events.
Rate:
Favorite:
You must Login to add a comment
  • This item doesn't have any comments

Enter your email address to receive important announcements and updates through the ASPR TRACIE Listserv.